Trials / Completed
CompletedNCT00011973
Chemotherapy in Treating Patients With Advanced Kidney Cancer
A Phase Two Study Of Fenretinide In Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Barbara Ann Karmanos Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have advanced kidney cancer.
Detailed description
OBJECTIVES: * Determine the response rate of patients with advanced renal cell carcinoma treated with fenretinide. * Determine progression-free and overall survival of this patient population treated with this drug. * Determine the quantitative and qualitative toxic effects of this drug in these patients. OUTLINE: Patients receive oral fenretinide twice a day for 7 days. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. PROJECTED ACCRUAL: Approximately 18-35 patients will be accrued for this study within 9-21 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fenretinide |
Timeline
- Start date
- 2000-12-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2003-08-08
- Last updated
- 2013-04-05
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00011973. Inclusion in this directory is not an endorsement.